Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.73 |
| ▸ | ESR1 | P03372 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.73 |
| ▸ | ATM | Q13315 | 3/20 | 0.73 |
| ▸ | PGR | P06401 | 3/20 | 0.73 |
| ▸ | AR | P10275 | 3/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.67 |
| ▸ | SHBG | P04278 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17419466 | 1.00 | LMNA (0.73) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL1315380 | 1.00 | LMNA (0.73) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL547938 | 1.00 | LMNA (0.73) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL17419453 | 1.00 | LMNA (0.73) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL547226 | 0.97 | LMNA (0.80) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL4333126 | 0.96 | LMNA (0.75) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL40564 | 0.96 | LMNA (0.75) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL11102416 | 0.96 | LMNA (0.75) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL9404736 | 0.94 | LMNA (0.77) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL7633202 | 0.93 | LMNA (0.73) | LMNAESR1SMN1; SMN2ADORA3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310928-B2 | Enthesis healing | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-05-27 | — | — | US | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-20180305742-A1 | USE OF ESTROGENIC COMPOUNDS TO MANIPULATE THE BACTERIAL COMPOSITION OF VAGINAL COMMUNITIES | UNIVERSITY OF IDAHO (US) | 2018-10-25 | — | — | US | claimed |
| US-8110565-B2 | Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| WO-1997047324-A1 | METHOD OF USING ALOE VERA AS A BIOLOGICAL VEHICLE | UNIVERA PHARMACEUTICALS, INC. (US) | 1997-12-18 | — | — | WO | claimed |
| EP-0346014-B1 | Therapeutic product for the treatment of peri- or postmenopausal conditions | ZENECA LTD (GB) | 1994-08-03 | — | — | EP | claimed |
| US-5183814-A | Administering estrogen and antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-02 | — | — | US | claimed |
| EP-0256668-B1 | METHOD FOR TREATING MALE SEXUAL DYSFUNCTION | UNIVERSITY OF FLORIDA (US) | 1992-11-04 | — | — | EP | claimed |
| EP-0346014-A1 | Therapeutic product for the treatment of peri- or postmenopausal conditions | ZENECA LIMITED (GB) | 1989-12-13 | — | — | EP | claimed |
| US-4863911-A | Method for treating male sexual dysfunction | UNIVERSITY OF FLORIDA (US) | 1989-09-05 | — | — | US | claimed |
| EP-0256668-A2 | Method for treating male sexual dysfunction | UNIVERSITY OF FLORIDA (US) | 1988-02-24 | — | — | EP | claimed |
| EP-0220844-A2 | Use of estrogen-dihydropyridine compounds for weight control | UNIVERSITY OF FLORIDA (US) | 1987-05-06 | — | — | EP | claimed |
| US-4617298-A | STEROIDS | UNIVERSITY OF FLORIDA (US) | 1986-10-14 | — | — | US | claimed |
| US-4298594-A | BENEFICIAL ALTERATION OF PHARMACODYNAMICS | ARTHUR D. LITTLE, INC. (US) | 1981-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | LMNA 344/4885ESR1 1524/4885SMN1; SMN2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.